StreetInsider.com News Articles

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Mon, 10 Aug 2026 08:00:00 -0400

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing

Alpha Tau reports 100% response rate in head and neck cancer combo trial

Tue, 21 Jul 2026 08:32:13 -0400

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced clinical study results showing a 100% objective response rate among nine evaluable elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) treated with its Alpha DaRT device in combination with pembrolizumab (Keytruda).
The results were presented at the American Head and Neck Society 12th International Conference on Head and Neck Cancer in Boston, Massachusetts, held July 18-22, 2026.
Among the nine evaluable patients, the combination produced four complete responses and five partial responses. Median overall survival was 18.2 months and median progression-free survival was 5.4 months. For comparison, pembrolizumab